Novel HIV-1 fusion peptide immunogens using glycan-engineered alphavirus-like particles
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Immunofocusing on conserved, subdominant epitopes is critical for vaccines against highly diverse viruses such as HIV-1, influenza, and SARS-CoV-2. The eight-residue N-terminus of the HIV-1 fusion peptide (FP) is one such example of a promising yet small target. We developed new FP immunogens using three alphavirus-like particles (VLPs) and introduced additional glycans to mask shared carrier-specific epitopes. In two independent guinea pig studies, sequential immunization with heterologous carriers enhanced FP-directed antibody titers, which were further improved with glycan engineering. Separately, using diverse FP variants sharing the same N-terminal six amino acids increased neutralizing antibody titers. When combined, these two strategies led to higher FP-directed titers and, after Env trimer boosting, induced FP-directed neutralizing antibodies against multi-clade wild-type HIV-1 in nearly all animals. These findings established the importance of minimizing recurrent off-target epitopes across immunizations and support the engineered VLPs as a promising platform for peptide immunization.
Highlights
-
Novel HIV-1 fusion peptide immunogens using glycan-engineered alphavirus-like particles
-
Improved FP-directed response by minimizing recurrent carrier-specific epitopes across immunizations
-
Improved neutralizing response by sequential immunization with diverse FP variants
-
FP-directed antibodies neutralizing multi-clade wildtype viruses in nearly all animals
